Daniel S. Jaffee
Analyst · Robert Smith from the Center for Performance
Yes. I mean, so I guess I'll take the second question first. Way more of a skimming strategy than a volume strategy in Verge. And by that, what I mean is, we're using Verge -- it really is -- it's outstanding product. It is eye-popping when consumers see this engineered granule. So we need to find customers who can leverage the benefits of uniformity and 0 dust, and there are many of them out there. And when they do, price is not even an issue because they're getting -- they're being able to put less active ingredient on it. They're being able to have a tighter pattern when they spray it out onto the field, so there's less chemical going out. I mean, there's so many tangential benefits to what our product can do that when that all happens, the value proposition is such that price, not that it's irrelevant, but you're not competing with anybody else. So it's not, oh, your price is $5 a ton too high. If you lower it, you'll have the business. So we're really zeroing in on those accounts that it really resonates with. Then, if price is really the issue for them and there are many accounts where price is the issue, if they're in a large volume, very competitive industry and maybe the active ingredient isn't as expensive or they're not as focused on dust and the tightness of pattern, then Agsorb is a great product, which we've been making for years and we have a lot of capacity, and we can make it at a very low price. So we really have the whole suite of products targeted at the whole range of the market. But I'm glad we have not gone to Phase 2 or 3 of Verge because what we're finding is, we can get in the door with Verge and then if they have a high volume opportunity but the price is really important to them, we're able to come in with Agsorb, Verge got us at the table, but Agsorb seals the deal. And then, that's how we're going to keep doing it. So while the sales of Verge might be down a little bit this year, the profitability is multiple fold better than what it's been in the past. And then if you include, like I said, that sort of extra benefit of it getting us to the table and then we're able to sell Agsorb in for price-sensitive applications, it's been a big winner, and it's going to continue to be a big winner. So -- but it's not going to be high volume at the moment, applications. So the big guys, you can think of who would be a major Ag Chem company and so forth. If they're buying 20,000, 30,000, 40,000 tons of carrier, they're not ready to leap to the price point that we're ready at. So -- but they're more than happy to buy Agsorb, which is a good thing. On Calibrin, yes. I don't want to get too much into it until it's ready, but we're -- the core products, A and Z, are working very well. We're working very heavily on a, what we'll call, our clay plus, which is our clay with added benefit to all around the area of gut health and providing nonantibiotic solutions to what has historically only been treated with antibiotics. And there's a big wave in the food chain production industry to get out of antibiotics because rightly so, people feel that if it's in the animal, it's going to end up in the meat, then it's going to end up in the person who's eating the meat. And ultimately, the human beings become less and less reactive to antibiotic treatments. So there's definitely a big wave globally to get out of antibiotics, and our clays are proving and in vivo trials at the moment to work better than what are generally recognized as the best antibiotic solution, and we're nonantibiotics. So it's going to take time. We got more some in vivo trials to go. It's all about the data. It can't be smoke and mirrors, it's got to be real. At the moment, we've cleared the hurdles and it's real. But we probably have a couple more hurdles to clear before we'll be selling this clay plus product on a widespread basis in the market. But at the moment, it's very exciting.